drugset / Trial / NCT06751589

A Study of a Weight Loss Intervention in People With Endometrial Cancer

NCT06751589

Phase 0 Recruiting 36 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.

Timeline

Start
2024-12-19
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 5 mg Subcutaneous

Indications